Abstract 227P
Background
Even though patients with non-muscle invasive urothelial carcinoma (NMIUC) show favorable survival rates, more than a half of them relapse during follow-up, while up to 20% progress to muscle-invasive urothelial carcinoma (MIUC). As the presence of invasion confers significant prognostic and therapeutic implications for these patients, its accurate detection is imperative; this has prompted the search for biomarkers predictive of invasion, using mostly genomic analysis. In contrast to the extensive genome-based research published so far in the field of BUC, studies utilizing in-depth proteomic analysis on patient-derived tissue samples, directed toward the identification of biomarkers predictive of tumor invasion, have barely been performed.
Methods
A total of 265 radical cystectomy specimens were selected from the Department of Pathology, Seoul National University Hospital (SNUH). This cohort consisted of 39 formalin-fixed paraffin embedded (FFPE) whole tissue samples used for the in-depth proteomics analysis, besides 226 BUC cases processed and analyzed as tissue microarrays (TMAs) to validate the in-depth proteomics findings along with in vitro testsFor proteomic analysis, 31 tissue specimens, consisting of 9 IUP, 12 PUC, and 10 normal urothelium (NU), were included. Machine learning-based feature selection for candidate markers For validation of IUP, we performed immunohistochemical staining in an independent valid. ation cohort composed of 25 IUP and 16 PUC with inverted growth.
Results
Validation of TUBB6 and TGFBI as potential predictive markers of muscle-invasive urothelial carcinoma (MIUC) and prognosis determinants. tubulin beta 6 class V (TUBB6) and TGFBI mRNA high expression and TUBB6 and TGFBI protein expression levels among NMIUC (pTa/pT1) and MIUC (pT2-pT4) (SNUH). From the overall proteomic landscape, The immunohistochemical validation PYGB as a specific biomarker to distinguish between IUP and PUC with inverted growth.
Conclusions
We propose TUBB6 as a novel IHC biomarker to predict invasion and poor prognosis, also select the optimal treatment in BUC patients. We suggest PYGB as a promising immunohistochemical marker for IUP diagnosis in routine practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract